Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
In this open-label, single-arm, phase 2 study, 40 eligible patients with EGFR mutated stage
IIIA-IIIB resectable NSCLC will be recruited to receive furmonertinib for 9 weeks combined
with cisplatin/pemetrexed for 3 cycles (21 d/cycle) as neoadjuvant therapy before radical
surgery. Radiological and pathological evaluations will be performed before and after the
neoadjuvant therapy to assess the efficacy of treatment. Adverse events during neoadjuvant
therapy, disease and survival status will also be collected in the study.